Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/62648
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMohsin, M-
dc.contributor.authorShoaib, M-
dc.contributor.authorAnas, M-
dc.date.accessioned2023-09-29T11:48:05Z-
dc.date.available2023-09-29T11:48:05Z-
dc.date.issued2023-07-
dc.identifier.issn0975-1068 (Online); 0972-5938 (Print)-
dc.identifier.urihttp://nopr.niscpr.res.in/handle/123456789/62648-
dc.description543-546en_US
dc.description.abstractIn the case of established post herpetic neuralgia (PHN), the medication is simple analgesics, opioid derivatives (Tramadol), antidepressant (Amitriptyline), anticonvulsant (Carbamazepine), GABA agonist (Gabapentin & Pregabaline), etc., but the benefit of treatment does not outweigh its cost and hazards. Therefore, there is always an area of thrust that arises to find out a cost-effective and hazardless medication before expert of Physical medicine, Regimenist, Dermatologist, and general Physicians. As far as Unani Pharmacopeia is concerned there are several single and compound drugs indicated in ailment like wajaula’asab (neuralgia) but their efficacy in terms of documentation and validation is not established yet. A very important formulation prepared from Dawakhana Tibbiya College, Aligarh Muslim University Aligarh is usually indicated for neuralgic pain in routine practice. As far as PHN is concerned there is no medication indicated in classical literature. Therefore, this study was designed to find out the therapeutic efficacy of Qurse Asabi in comparison to most commonly prescribed allopathic medicines i.e., Neurokind-G containing Methyl Cobalamin 1500 mcg and Gabapentin 100 mg as a controlled drug while the Qurse Asabi is given as a test drug. The methodology was followed as per the Good Clinical Practice (GCP) guideline. Results were much interesting and encouraging which was also found statistically significant (t=10, p<0.0001).en_US
dc.language.isoenen_US
dc.publisherNIScPR-CSIR,Indiaen_US
dc.relation.ispartofseriesInt Cl.23: A61K 9/00, A61K 36/00, A61K 45/00en_US
dc.sourceIJTK Vol.22(3) [July 2023]en_US
dc.subjectHerpes zosteren_US
dc.subjectPost herpetic neuralgia (PHN)en_US
dc.subjectWajaula’asaben_US
dc.titleA comparative parallel design clinical study of Qurse Asabi in cases of post herpetic neuralgiaen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.56042/ijtk.v22i3.5732en_US
Appears in Collections:IJTK Vol.22(3) [July 2023]

Files in This Item:
File Description SizeFormat 
IJTK 22(3) 543-546.pdf399.38 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.